Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005-2015.
Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005-2015.
复制标题
DOI：
10.1016/j.amepre.2017.08.003
复制
发表时间：
2017-12
影响因子：
5.5
通讯作者：
Marcus PM
中科院分区：
文献类型：
--
作者：
Berkowitz Z;Li J;Richards TB;Marcus PM
基于前列腺特异性抗原的前列腺癌筛查建议越来越重视 55-69 岁的男性。当前研究的目标是描述基于人群的前列腺特异性抗原检测的模式以及该年龄组的详细信息。 2017 年对 2005 年至 2015 年的全国健康访谈调查进行了分析，根据各年龄组（40-54 岁、55-69 岁、≥70 岁）以及风险组（定义为非裔美国男性或有前列腺癌家族史的男性与其他男性）的自我报告数据来估计过去一年的常规前列腺特异性抗原检测情况。使用逻辑回归，通过预测边际和 99% CI 的比率来评估按年龄和风险组划分的连续调查年份之间的差异。 55-69岁男性前列腺特异性抗原检测从2008年的43.1%高位（95% CI=40.3, 46.1）下降到2013年的32.8%低位（95% CI=30.8, 34.7），2015年没有显着变化，为33.8%（95% CI=31.3， 36.4）。年龄≥70岁的男性在所有调查年份中的患病率一直很高，从2008年的51.1%到2015年的36.4%。非裔美国男性、有前列腺癌家族史的男性和其他男性的患病率随着时间的推移绝对下降了5%，但这种下降仅在其他男性中显着。尽管有所下降，但在研究期间，55-69岁男性前列腺特异性抗原检测的绝对变化很小（9.3%）。年龄≥70 岁的男性，其获益不太可能超过危害，但检测普及率仍然很高。
Recommendations for prostate-specific antigen-based screening for prostate cancer are placing increasing emphasis on men aged 55–69 years. The goal of the current study is to describe patterns of population-based prostate-specific antigen testing with details about that age group. National Health Interview Surveys from 2005 to 2015 were analyzed in 2017 to estimate routine prostate-specific antigen testing in the past year from self-reported data by age group (40–54, 55–69, ≥70 years), and also by risk group, defined as African American men or men with a family history of prostate cancer versus other men. Differences between successive survey years by age and risk groups were assessed by predicted margins and rate ratios with 99% CIs, using logistic regressions. Prostate-specific antigen testing among men aged 55–69 years decreased from a high of 43.1% (95% CI=40.3, 46.1) in 2008 to a low of 32.8% (95% CI=30.8, 34.7) in 2013, with no significant change in 2015 at 33.8% (95% CI=31.3, 36.4). Men aged ≥70 years had consistently high prevalence in all survey years, ranging from 51.1% in 2008 to 36.4% in 2015. African American men, men with a family history of prostate cancer, and other men showed a 5% absolute decrease over time, but this reduction was significant only in other men. Despite decreases, the absolute change in prostate-specific antigen testing for men aged 55–69 years was small (9.3%) over the study period. Men aged ≥70 years, for whom the benefits are unlikely to exceed the harms, continue to have consistently high testing prevalence.
登录
查看更多内容
影响因子：
39.2
作者：
Berg, AO;Allan, JD;Woolf, SH
通讯作者：
Woolf, SH
影响因子：
3.9
作者：
Li, Jie;Wang, Xuan-Ce;Wang, Qiang
通讯作者：
Wang, Qiang
影响因子：
39.2
作者：
Qaseem, Amir;Barry, Michael J.;Shekelle, Paul
通讯作者：
Shekelle, Paul
影响因子：
39.2
作者：
Moyer, Virginia A.
通讯作者：
Moyer, Virginia A.
影响因子：
39.2
作者：
通讯作者：
--